Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Herman Burger

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2010
Drug transporters and imatinib treatment: implications for clinical practiceKarel Eechoute, Alex Sparreboom, Herman Burger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic responseHerman Burger, John A Foekens, Maxime P Look, et al.
Cancer Biology & Therapy|June 23, 2005
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumpsHerman Burger, Hans van Tol, Mariël Brok, et al.
Investigational New Drugs|November 20, 2012
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumorsJohn Marshall, Jimmy Hwang, Ferry A L M Eskens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumorsFerry A L M Eskens, Maja J A de Jonge, Pankaj Bhargava, et al.
The Prostate|March 22, 2016
Understanding taxanes in prostate cancer; importance of intratumoral drug accumulationEllen de Morrée, Robert van Soest, Ashraf Aghai, et al.
Molecular Pharmacology|June 26, 2015
Lysosomal Sequestration Determines Intracellular Imatinib LevelsHerman Burger, Alexander T den Dekker, Sandra Segeletz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2014
Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumorsDiane A J van der Biessen, Herman Burger, Peter de Bruijn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2013
Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumorsFerry A L M Eskens, Francisco J Ramos, Herman Burger, et al.
Clinical Pharmacokinetics|February 4, 2015
Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical EvidenceJacqueline S L Kloth, Lisette Binkhorst, Annelieke S de Wit, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2010
Drug transporters and imatinib treatment: implications for clinical practiceKarel Eechoute, Alex Sparreboom, Herman Burger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic responseHerman Burger, John A Foekens, Maxime P Look, et al.
Cancer Biology & Therapy|June 23, 2005
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumpsHerman Burger, Hans van Tol, Mariël Brok, et al.
Investigational New Drugs|November 20, 2012
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumorsJohn Marshall, Jimmy Hwang, Ferry A L M Eskens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumorsFerry A L M Eskens, Maja J A de Jonge, Pankaj Bhargava, et al.
The Prostate|March 22, 2016
Understanding taxanes in prostate cancer; importance of intratumoral drug accumulationEllen de Morrée, Robert van Soest, Ashraf Aghai, et al.
Molecular Pharmacology|June 26, 2015
Lysosomal Sequestration Determines Intracellular Imatinib LevelsHerman Burger, Alexander T den Dekker, Sandra Segeletz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2014
Phase I study of RGB-286638, a novel, multitargeted cyclin-dependent kinase inhibitor in patients with solid tumorsDiane A J van der Biessen, Herman Burger, Peter de Bruijn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2013
Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumorsFerry A L M Eskens, Francisco J Ramos, Herman Burger, et al.
Clinical Pharmacokinetics|February 4, 2015
Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical EvidenceJacqueline S L Kloth, Lisette Binkhorst, Annelieke S de Wit, et al.
Pageof 3